While the Patent Trial and Appeal Board invalidates Orange Book-listed patents less than 20 percent of the time, it accepts 66 percent of petitions from generic drugmakers and takes no…
The post What We Know From 4-Plus Years of Drug Patent Chall…
What We Know From 4-Plus Years of Drug Patent Challenges Heard by the PTAB Read Post »
By Ed Lamb, DrugPatentWatch Writer Pilot projects are underway, but regulatory and stakeholder buy-in concerns remain When pharmaceutical supply chain stakeholders met recently to discuss applications for blockchain technology, they…
The post How…
How Pharmaceutical Blockchain Technology Challenges Can Be Overcome Read Post »
By Ed Lamb, DrugPatentWatch writer Under a new commissioner dedicated to bolstering competition to reduce prices, the agency is redoing a raft of rules and guidances to speed ANDA approvals…
The post FDA Pushes to Reduce Single-Source Generics, I…
FDA Pushes to Reduce Single-Source Generics, Increase Biosimilars Read Post »